Physician profile
Paul Lapoint
NPI 1790782761
$3,704.32
in general payments reported to CMS, 2019-2025
32 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $82.09 · 2021: $316 · 2022: $2,230 · 2023: $233 · 2024: $202 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $613.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $1,968.30 | 2019-2022 | |
| Smith+Nephew, INC. | $335.81 | 2019-2024 | Journey II, Legion, Healicoil |
| Ferring Pharmaceuticals INC. | $314.25 | 2019-2025 | Euflexxa |
| Pacira Therapeutics, INC. | $117.32 | 2019-2021 | |
| Abbott Laboratories | $99.45 | 2021-2025 | Proclaim |
| Innovation Technologies INC | $98.28 | 2022 | |
| Horizon Therapeutics Plc | $93.43 | 2020-2021 | |
| Bioventus LLC | $83.72 | 2022-2025 | Exogen Ultrasound Bone Healing System, Xcell |
| Pacira Pharmaceuticals Incorporated | $69.88 | 2019-2023 | Zilretta |
| Heraeus Medical, LLC. | $66.75 | 2019-2022 | |
| Prodigy Surgical Distribution, INC. | $48.65 | 2022 | |
| Ibsa Pharma INC. | $39.41 | 2024 | Tirosint, Licart, Flector |
| Misonix INC | $31.94 | 2021 | |
| Vericel Corporation | $28.41 | 2023 | Maci |
| Depuy Synthes Sales INC. | $25.84 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $21.46 | 2021 | |
| Abbvie INC. | $20.51 | 2025 | |
| Solventum Corporation | $20.00 | 2024 | Prevena |
| Ethicon US, LLC | $19.87 | 2019 | |
| Kci USA, INC. | $18.52 | 2022 | |
| Pfizer INC. | $17.99 | 2020 | |
| Fidia Pharma USA INC. | $17.76 | 2023 | Hymovis, Triluron |
| Orthofix Medical, INC. | $17.70 | 2021 | |
| Davol INC. | $16.88 | 2022 | |
| Becton, Dickinson and Company | $14.99 | 2022 | |
| Arthrosurface Incorporated | $14.80 | 2019 | |
| Dynasplint Systems INC. | $14.60 | 2024 | Dynasplint |
| Baudax Bio INC. | $14.22 | 2021 | |
| Stryker Corporation | $13.88 | 2019 | |
| Allergan, INC. | $13.51 | 2019 | |
| Avanos Medical | $13.28 | 2023 | Grpro 2.1 |
| Endo Pharmaceuticals INC. | $12.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lapoint listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.